SK10332003A3 - Farmaceutický prostriedok na inhibíciu rastu nádorov a/alebo nádorových buniek - Google Patents

Farmaceutický prostriedok na inhibíciu rastu nádorov a/alebo nádorových buniek Download PDF

Info

Publication number
SK10332003A3
SK10332003A3 SK1033-2003A SK10332003A SK10332003A3 SK 10332003 A3 SK10332003 A3 SK 10332003A3 SK 10332003 A SK10332003 A SK 10332003A SK 10332003 A3 SK10332003 A3 SK 10332003A3
Authority
SK
Slovakia
Prior art keywords
taxane
tumor
cells
formula
dose
Prior art date
Application number
SK1033-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Joseph Fargnoli
William C. Rose
Pamela Trail
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SK10332003A3 publication Critical patent/SK10332003A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Carpets (AREA)
  • Epoxy Compounds (AREA)
SK1033-2003A 2001-02-28 2002-02-26 Farmaceutický prostriedok na inhibíciu rastu nádorov a/alebo nádorových buniek SK10332003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27194401P 2001-02-28 2001-02-28
PCT/US2002/005971 WO2002067928A2 (en) 2001-02-28 2002-02-26 Metronomic dosing of taxanes for inhibiting tumor growth

Publications (1)

Publication Number Publication Date
SK10332003A3 true SK10332003A3 (sk) 2005-03-04

Family

ID=23037749

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1033-2003A SK10332003A3 (sk) 2001-02-28 2002-02-26 Farmaceutický prostriedok na inhibíciu rastu nádorov a/alebo nádorových buniek

Country Status (31)

Country Link
EP (1) EP1372636B1 (el)
JP (1) JP2004538253A (el)
KR (1) KR20030086276A (el)
CN (1) CN1533273A (el)
AR (1) AR033609A1 (el)
AT (1) ATE331511T1 (el)
BG (1) BG108167A (el)
BR (1) BR0207519A (el)
CA (1) CA2439299A1 (el)
CY (1) CY1105468T1 (el)
CZ (1) CZ20032232A3 (el)
DE (2) DE60212813T2 (el)
DK (1) DK1372636T3 (el)
EE (1) EE200300413A (el)
ES (1) ES2211374T3 (el)
HR (1) HRP20030775A2 (el)
HU (1) HUP0402115A2 (el)
IL (1) IL157356A0 (el)
IS (1) IS6924A (el)
MX (1) MXPA03007655A (el)
NO (1) NO20033809L (el)
PE (1) PE20020955A1 (el)
PL (1) PL373376A1 (el)
PT (1) PT1372636E (el)
RU (1) RU2003129233A (el)
SK (1) SK10332003A3 (el)
TR (1) TR200400375T3 (el)
UY (1) UY27185A1 (el)
WO (1) WO2002067928A2 (el)
YU (1) YU66603A (el)
ZA (1) ZA200306450B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
EP2286794B8 (en) * 2003-10-15 2016-06-01 SynCore Biotechnology CO., LTD Use of cationic liposomes comprising paclitaxel
AU2006243337B2 (en) * 2005-05-04 2011-09-29 Syncore Biotechnology Co., Ltd Method of administering a cationic liposomal preparation comprising paclitaxel
US8168216B2 (en) 2006-03-22 2012-05-01 Medigene Ag Treatment of triple receptor negative breast cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9809694A (pt) * 1997-05-27 2000-10-03 Baker Norton Pharma Processo e composição para administração de taxanos oralmente a pacientes humanos
US6750246B1 (en) * 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents

Also Published As

Publication number Publication date
KR20030086276A (ko) 2003-11-07
NO20033809D0 (no) 2003-08-27
EP1372636A2 (en) 2004-01-02
YU66603A (sh) 2006-08-17
TR200400375T3 (tr) 2004-04-21
HUP0402115A2 (hu) 2005-02-28
ZA200306450B (en) 2004-11-19
WO2002067928A2 (en) 2002-09-06
JP2004538253A (ja) 2004-12-24
RU2003129233A (ru) 2005-02-10
DE60212813D1 (de) 2006-08-10
DK1372636T3 (da) 2006-11-06
CZ20032232A3 (en) 2004-06-16
MXPA03007655A (es) 2003-12-04
ES2211374T3 (es) 2007-03-01
EP1372636B1 (en) 2006-06-28
IL157356A0 (en) 2004-02-19
AR033609A1 (es) 2003-12-26
DE60212813T2 (de) 2007-01-18
BR0207519A (pt) 2005-03-08
PE20020955A1 (es) 2002-10-30
DE02723255T1 (de) 2004-07-15
IS6924A (is) 2003-08-22
CA2439299A1 (en) 2002-09-06
NO20033809L (no) 2003-10-23
PL373376A1 (en) 2005-08-22
EE200300413A (et) 2003-12-15
UY27185A1 (es) 2002-09-30
HRP20030775A2 (en) 2005-02-28
CY1105468T1 (el) 2010-04-28
ATE331511T1 (de) 2006-07-15
WO2002067928A3 (en) 2003-10-09
PT1372636E (pt) 2006-09-29
BG108167A (en) 2004-09-30
ES2211374T1 (es) 2004-07-16
CN1533273A (zh) 2004-09-29

Similar Documents

Publication Publication Date Title
CN100522967C (zh) 含磷化合物及其应用
ES2700450T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
JP2007538105A (ja) Gst活性化抗癌化合物による治療による別の抗癌療法の増感および/または別の抗癌療法の副作用の改善
US20220313642A1 (en) Tyrosine derivatives and compositions comprising them
JP2008509948A5 (el)
US20040143004A1 (en) Metronomic dosing of taxanes
EP3911416B1 (en) Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
CA3045110A1 (en) Tyrosine derivatives and compositions comprising them
EP3986389A1 (en) Cannabinoid conjugate molecules
AU2017283653B9 (en) Porphyrin compounds and compositions useful for treating cancer
SK10332003A3 (sk) Farmaceutický prostriedok na inhibíciu rastu nádorov a/alebo nádorových buniek
EP3421039A1 (en) Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
EP4378473A1 (en) Her2 vaccine composition
EP3673907A1 (en) Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component
TW202011946A (zh) 以bet抑制劑及蛋白酶體抑制劑之組合療法
RU2697551C2 (ru) Новые производные peg
KR20230124989A (ko) 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의테트라히드로인다졸 유도체의 제조
WO2019028270A1 (en) MATERIALS AND METHODS FOR DELETING AND / OR TREATING BONE-RELATED DISEASES AND SYMPTOMS
AU2002254048A1 (en) Metronomic dosing of taxanes for inhibiting tumor growth
EP1623706A2 (en) Metronomic dosing of taxanes for inhibiting tumor growth
RU2822394C1 (ru) Способы лечения
KR20240058898A (ko) 히스톤 디아세틸라제 6 및 열 충격 단백질 90의 이중 억제제
WO2009104152A1 (en) Combination treatment for ovarian cancer
KR20220054853A (ko) 치료 방법
CN102858764A (zh) 嘧啶基吲哚化合物

Legal Events

Date Code Title Description
FC9A Refused patent application